BTIG Downgrades Morphic Therapeutic (MORF) to Neutral, 'becoming increasingly difficult to defend'
Tweet Send to a Friend
BTIG analyst Julian Harrison downgraded Morphic Therapeutic (NASDAQ: MORF) from Buy to Neutral.The analyst comments "We do not think that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
